Fortress Biotech Inc (FBIO) - News Archive

Fortress Biotech Clinches Significant Deal with Checkpoint Therapeutics: $28 Million Incoming and Future Royalties AheadIn a landmark move, Fortress Biotech has announced the closing of its agreement to sell its subsidi...

Fortress Biotech Makes Strategic Move with $8 Million Registered Direct Offering to Support Growth and InnovationMIAMI, Sept. 20, 2024 Fortress Biotech, Inc. (Nasdaq: FBIO), a dynamic biopharmaceutical firm dedicated to...

The economic potential of Fortress: Extending debt maturity in anticipation of regulatory approvals and future growthFortress Biotech, Inc. recently announced the extension of the maturity of its long-term debt, signali...

In a recent press release, Fortress Biotech, Inc. announced that its Board of Directors has decided to pause the payment of dividends on the Company s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock unti...

Cytomegalovirus (CMV) is a significant concern in patients undergoing liver transplantation, as it poses a serious threat to both graft and patient survival. In light of this challenge, Fortress Biotech s majority-owned...

Fortress Biotech Inc. and Cyprium Therapeutics have recently announced a significant milestone in the development of a potential treatment for Menkes disease. Encouraging preclinical studies have shown the potential to...

Fortress Biotech Successfully Completes Registered Direct Offering, Securing Promising Future for ShareholdersMIAMI, Jan. 03, 2024 - Fortress Biotech, Inc. (Nasdaq: FBIO), a renowned biopharmaceutical company known for...

Fortress Biotech, an innovative biopharmaceutical company dedicated to acquiring, developing, and commercializing promising therapeutic products and candidates, recently unveiled a groundbreaking definitive agreement fo...